Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2000-02-22
2002-04-16
Caputa, Anthony (Department: 1642)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C424S093210, C435S069300, C435S252300, C435S320100, C514S04400A, C536S023500
Reexamination Certificate
active
06372490
ABSTRACT:
FIELD OF THE INVENTION
The invention relates generally to polypeptides and nucleic acids and more particularly to polypeptides that interact with the MDM2 polypeptide, and nucleic acids encoding these MDM2-interacting polypeptides.
BACKGROUND OF THE INVENTION
The gene MDM2 has been implicated in a variety of cellular processes. In addition, altered expression of MDM2 has been associated with several disease states, including cancer. For example, the MDM2 gene has been shown to be abnormally up-regulated in human tumors and tumor cell lines. In addition, amplification of MDM2 genes has been reported in a variety of cancers, e.g., human sarcoma, glioma, squamous cell carcinoma, breast cancer, astrocytoma, leukemia and lymphoma. These results indicate that the MDM2 protein plays a role in human carcinogenesis.
MDM2 has been reported to interact with, i.e., bind to other proteins. Some of these proteins have themselves been associated with tumorigenesis. For example, MDM2 has been reported to form a complex with the p53 tumor suppressor and to block the growth suppressive functions of p53. In addition, overexpression of MDM2 has been shown to block the transactivation, cell cycle arrest (S/G2 phase) and apoptotic functions of p53.
MDM2 has also been shown to interact with the retinoblastoma tumor suppressor protein pRb, and the E2F-1 and DP1 transcription factors. Through MDM2's activation of E2F and DP1, MDM2 is thought to stimulate a G1 to S transition in the cell cycle. In addition, MDM2 has also been reported to interact with Numb, a protein involved in the determination of cell fate.
SUMMARY OF THE INVENTION
The invention is based in part on the discovery of a novel polypeptide, named MDM Interacting Protein, or “MDMIP”, based on its ability to bind to the MDM2 polypeptide.
In one aspect, the invention includes a purified complex that includes a polypeptide which includes an MDMIP binding domain (or region) of an MDM2 polypeptide and a polypeptide which includes an MDM2 binding domain (or region) of an MDMIP polypeptide. The complex can thus include, e.g, an MDM2 polypeptide and an MDMIP polypeptide. In various embodiments, the MDM2 polypeptide, the MDMIP polypeptide, or both polypeptides within the complex, are human polypeptides.
In some embodiments, the MDM2 binding domain of the MDM2 polypeptide includes an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% or more identical to the amino acid sequence of a region of polypeptide that includes the amino acid sequence of SEQ ID NO:2.
In some embodiments, the MDMIP binding domain of the MDM2 polypeptide includes an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% or more identical to the amino acid sequence of a region of polypeptide that includes the amino acid sequence encoded by the nucleic acid sequence having GenBank accession number M92424. In some embodiments, the MDMIP binding domain includes the amino acid sequence of SEQ ID NO:4, e.g., it can include the amino acid sequence of the MDM2 polypeptide encoded by the nucleic acid sequence of M9424 (SEQ ID NO:6). Thus, in some embodiments, the MDMIP binding domain of the MDM2 polypeptide is present in a polypeptide which includes the amino acid sequence of an MDM2 polypeptide, e.g., a polypeptide including at least that portion of the amino acid sequence of SEQ ID NO:4 that is sufficient to bind to an MDMIP polypeptide.
If desired, one or more of the polypeptides in the MDM2-MDMIP complex, e.g., the MDM2-binding domain of the MDMIP polypeptide, the MDMIP-binding domain of the MDM2 polypeptide, or both is labeled.
In other embodiments, the complex includes a fragment of an MDMIP polypeptide that includes an MDM2-binding domain, a fragment of an MDM2 polypeptide that includes an MDMIP-binding domain, or both fragments.
Another aspect of the invention includes a chimeric polypeptide that includes a region of an MDMIP polypeptide covalently linked, e.g., via a peptide bond, to a region of an MDM2 polypeptide. Preferably, the chimeric peptide includes 6, 8, 10, 12, 14, or 16 or more amino acids of an MDM2 polypeptide covalently linked to 6, 8, 10, 12, 14, 16 or more amino acids of an MDMIP polypeptide.
In some embodiments, the amino acids of the MDMIP-derived polypeptide in the chimeric polypeptide include an MDM2 binding domain. For example, the MDMIP-derived polypeptide can include a polypeptide which binds to MDM2 and, optionally, includes at least a portion of an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, or 99% or more identical to the amino acid sequence of SEQ ID NO:2.
Similarly, in some embodiments, the amino acids of the MDM2-derived polypeptide in the chimeric polypeptide include an MDMIP-binding domain. Thus, the MDM2 polypeptide can include a polypeptide which binds to MDMIP and, optionally, includes at least a portion of an amino acid sequence at least 80%, 85%, 90%, 95%, 98%, or 99% or more identical to the amino acid sequence of SEQ ID NO:4, i.e., a polypeptide having the amino acid sequence encoded by nucleic acids 312-963 of the nucleic acid sequence corresponding to GenBank accession number M92424.
In a further aspect, the invention includes an isolated MDMIP nucleic acid. In some embodiments, the MDMIP nucleic acid encodes an MDMIP polypeptide, e.g., the nucleic acid may include a nucleic acid that encodes a polypeptide at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or even 99% identical to a polypeptide which includes the amino acid sequence of SEQ ID NO:2.
The MDMIP nucleic acid may alternatively, or in addition, include a sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or even 99% identical to a nucleic acid which includes nucleic acids 1-222 of
FIG. 1
(SEQ ID NO:1).
Also provided by the invention is a vector including an MDMIP nucleic acid, as well as a cell that includes an MDMIP nucleic acid. The MDMIP nucleic acid in the cell may be present in a vector, i.e., the invention includes a cell that contains a vector in which an MDMIP nucleic acid is present.
Another aspect of the invention includes a purified MDMIP polypeptide with an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or even 99% or more identical to the amino acid sequence of SEQ ID NO:2. In some embodiments, the MDMIP polypeptide binds to an MDM2 polypeptide.
In a further aspect, the invention includes an isolated MDM2-derived nucleic acid fragment. The MDM2-derived nucleic acid is less than the full length of a full-length MDM2 nucleic acid, i.e., the nucleic acid includes less than the full length reading frame of a nucleic acid encoding a full length MDM2 polypeptide. In some embodiments, the MDM2-derived nucleic acid encodes an MDM2polypeptide fragment that is less than 491 amino acids, e.g, it is less than 450, 400, 350, 300, 250, 200, 150, 100, or 50 amino acids, and, optionally, binds an MDMIP polypeptide, e.g., a polypeptide having the amino acid sequence of SEQ ID NO:2. Alternatively, or in addition, the MDM2-derived nucleic includes a nucleic acid that encodes a polypeptide at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or even 99% identical to a polypeptide which includes the amino acid sequence of SEQ ID NO:4, and which is less than 491 amino acids in length and is greater than 4 amino acids in length. Preferably, the MDMIP-binding polypeptide is greater than 5, 6, 7, 8, 9, or 10 amino acids in length and is less than 25, 50, 75, 100, 150, 200, 250, 300, 350, 400 or 450 amino acids in length.
The MDM2-derived nucleic acid may alternatively, or in addition, include a sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or even 99% identical to a nucleic acid which includes the nucleic acid sequence of SEQ ID NO:3.
Also provided by the invention is a vector including the MDM2-derived nucleic acid, as well as a cell that includes an MDM2-derived nucleic acid. The MDM2-derived nucleic acid in the cell may be present in a vector, i.e., the invention includes a cell that contains a vector in which an MDM2-derived nucleic acid is present.
Another aspect of the invention includes a pu
Nandabalan Krishnan
Schulz Vincent
Yang Meijia
Caputa Anthony
CuraGen Corporation
Davis Natalie
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Nucleic acid encoding the MDM interacting protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid encoding the MDM interacting protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid encoding the MDM interacting protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2831906